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LETTER TO THE EDITOR 1 
NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA; THEIR 2 
CLINICAL IMPACT IN THE UK CLL4 TRIAL 3 
In chronic lymphocytic leukemia (CLL), ‘coding’ NOTCH1 mutations were initially detected in 4 
exon 34, where they result in truncation of the C-PEST regulatory protein sequence, with 5 
consequent impaired degradation of the Notch1 intracellular domain (NCID), constitutive 6 
activation of Notch signalling and increased cell survival and resistance to apoptosis 1-3. 7 
Mutations occur in 6-10% of cases at diagnosis, with increasing prevalence in advanced 8 
disease stages, treatment-refractory disease, and after transformation to Richter syndrome 9 
4,5. In diagnostic and clinical trial cohorts, patients with NOTCH1 mutations exhibited 10 
reduced survival 5,6. In 2015, Puente and colleagues identified recurrent ‘non-coding’ 11 
mutations clustered to the 3’ UTR of NOTCH1 in 2% (11/506) previously untreated patients 12 
with CLL or monoclonal B-cell lymphocytosis 7. The presence of these 3’UTR mutations cause 13 
a novel splicing event, preferentially between a cryptic donor site located in the last exon 14 
and a newly created acceptor site in the 3’UTR of exon 34, resulting in the removal of the 15 
PEST sequence and constitutive activation of downstream signalling 7. Patients with non-16 
coding NOTCH1 mutations had similar outcomes to those with coding mutations, with 17 
shorter time to first treatment and shorter overall survival than wild type cases 7,8.  18 
Given the highly variable natural history of CLL and the often-serendipitous date of initial 19 
diagnosis, we aimed to establish the clinical significance of non-coding NOTCH1 mutations in 20 
DNA samples available from 489 patients at enrolment to the United Kingdom Leukemia 21 
Research Fund Chronic Lymphocytic Leukemia 4 (UK LRF CLL4) chemotherapy trial 9. 22 
NOTCH1 3’ UTR mutations were identified by High Resolution Melt (HRM) analysis in whole 23 
genome amplified DNA (F: TGCTCGTTCAACTTCCCTTC; R: CAAGCAAGTTCTGAGAGCCA) and 24 
confirmed by Sanger sequencing of genomic DNA (F: CCTAACAGGCAGGTGATGCT; R: 25 
ATCTGGCCCCAGGTAGAAAC) The results were combined with the data pertaining to coding 26 
NOTCH1 mutations in the same patient cohort from our previous publication5. 53 patients 27 
with wild-type HRM traces were sequenced, and no additional non-coding mutations were 28 
identified. It is was not possible to differentiate between clonal and sub-clonal NOTCH1 29 
mutations using our HRM/Sanger approach. We defined associations between the presence 30 
of NOTCH1 coding and non-coding mutation and a comprehensive panel of clinical and 31 
biological features reported in previous CLL4 papers 10-13, by univariate logistic regression. 32 
Kaplan-Meier, log-rank test and Cox regression analysis were used to assess the impact of 33 
NOTCH1 status on survival using Stata, where overall (OS) and progression-free (PFS) 34 
survival were defined as time from randomization to death from any cause and to relapse 35 
needing treatment, progression or death from any cause at last follow-up, respectively.  36 
In addition to exon 34 coding mutations observed in 47/489 (9.6%) CLL4 patients, we 37 
detected an additional 11/489 (2.2%) patients harbouring the non-coding mutations 38 
139390152 A>G (n=7) and 139390145 A>G (n=4) (Figure 1A), both previously reported to 39 
result in aberrant NOTCH1 splicing 7. Importantly, the non-coding variants were mutually 40 
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exclusive to coding variants, constituting 19% of the total NOTCH1 mutational burden of 41 
CLL4 cases, with 11.8% of patients carrying either type of NOTCH1 mutation. NOTCH1 non-42 
coding mutations were not identified in cases with mutations of TP53, BIRC3, BRAF (V660E), 43 
MYD88 (L265P), NFKBIE and RPS15 mutations, but did co-occur with SF3B1 [n=2] and ATM 44 
[n=2] mutations (Figure 1B). Next, we evaluated the association between NOTCH1 45 
mutations and the main clinico-biological characteristics in CLL (Table S1). As expected, 46 
when all 58 mutations were considered together, NOTCH1 mutations were significantly 47 
more prevalent in CLL4 cases with unmutated IGHV genes (OR: 2.9, 95% CI: 1.4-6.2, 48 
P=0.005), CD38 (OR: 4.5, 95% CI: 2.3-8.7, P<0.001) and ZAP70 positivity (OR: 3.1, 95% CI: 49 
1.5-6.4, P=0.002), high expression of CLLU1 (OR: 2.33, 95% CI: 1.2-4.4, P=0.01), trisomy 12 50 
(OR: 4.0, 95% CI: 2.2-7.4, P<0.001) and ≥15x109/l absolute pro-lymphocytes (OR: 3.12, 95% 51 
CI: 2.0-7.9, P<0.001). However, for non-coding mutations on its own only the association 52 
with Trisomy 12 remained significant (OR: 5.6, 95% CI: 1.6-18.8, P=0.006), in spite of the 53 
limited number of cases with these mutations. Of the 364 deaths in CLL4 patients with 54 
NOTCH1 data, 14 (4%) were due to Richter’s syndrome (RS). With non-coding NOTCH1 55 
mutations included, four of fourteen (29%) Richter’s deaths occurred in patients with 56 
NOTCH1 mutation, an association that was non-significant (P=0.062). 57 
In our previous CLL4 study we confirmed the independent prognostic significance of a 58 
number of biomarkers including coding NOTCH1 mutations 5. In our current study, we 59 
determined the impact of coding and non-coding mutations on overall response rate (ORR), 60 
OS and PFS. Coding and non-coding mutations, inspected together or separately, were not 61 
associated with ORR in any of the three treatment arms (data not shown). Considered 62 
separately, univariate Cox regression analysis showed that patients with NOTCH1 non-63 
coding or coding mutations exhibited a significantly shorter OS (median survival times: 43.2 64 
and 54.8 months, respectively) than patients with wild-type NOTCH1 (median 74.6 months). 65 
Non-coding and coding NOTCH1 mutations were also associated with reduced PFS (median 66 
survival times: 22.0 and 13.0 months respectively) compared to the wild type NOTCH1 (28 67 
months). In further support of their clinical importance, cases with non-coding NOTCH1 68 
mutations showed a two-fold increase in the risk of mortality when compared to wild type 69 
(HR: 2.15, 95% CI: 1.17-3.92, P=0.013) and an 80% increase in the risk of progression or 70 
death (HR: 1.78, 95% CI: 0.98-3.24, P=0.05). The impact of coding and non-coding NOTCH1 71 
mutations together on OS was sustained in a multivariable model where NOTCH1 status was 72 
controlled for gender, age, stage, IGHV and SF3B1 mutational status, 11q deletion, and TP53 73 
mutation/ deletion (adjusted HR: 1.5, 95% CI: 1.0-2.1, P=0.04, Table 1). On the contrary, the 74 
association between NOTCH1 mutational status and PFS was not significant when adjusted 75 
for the other variables listed above (adjusted HR: 1.3, 95% CI: 0.9-1.9, P=0.108) Taken 76 
together, we show that NOTCH1 status, based on the presence of either mutational type, is 77 
an independent risk factor for OS but not for PFS. The association between OS or PFS and 78 
the occurrence of non-coding mutations could not be estimated reliably in a multivariable 79 
analysis because of the small number of cases with such mutations in our series. 80 
Finally, we attempted to quantify the improved discriminatory power of including non-81 
coding NOTCH1 mutations to coding mutations as a test to predict both the presence and 82 
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absence of PFS and OS events at last follow-up using sensitivity-specificity analysis. The 83 
analysis was carried out on all 489 cases. NOTCH1 coding mutations correctly predicted 84 
46/454 PFS (sensitivity of 10.1%) and 43/393 (sensitivity of 10.9%) OS events (Table S2A and 85 
S3A). As expected, the sensitivity for OS and PFS was higher when both mutational types 86 
were considered than when coding mutation alone was analysed: 13.7 versus 10.9% for OS 87 
and 12.6 versus 10.1% for PFS events (Table S2A and S3A). This increase reflected the fact 88 
that all 11 patients with non-coding NOTCH1 mutations exhibited an adverse OS and PFS 89 
event resulting in 100% specificity for non-coding NOTCH1 mutation as a test. Accuracy 90 
assesses the capability of a given biomarker to correctly predict both the presence and 91 
absence of a survival event. Coding NOTCH1 mutations displayed 16.4 and 27.6% accuracy 92 
for correctly predicting the presence or absence of a PFS and OS respectively. Accuracy was 93 
increased to 18.6 and 29.9% for PFS and OS respectively, when non-coding mutations were 94 
included in this analysis. The likelihood ratio ,LR+, which adjusts sensitivity for false positives 95 
and LR- which adjusts specificity for false negatives are prevalence-independent and their 96 
ratio, LR+/LR- (diagnostic odds ratio), is an indicator of the predictive power of the 97 
biomarker. A biomarker with a higher LR+/LR- value is a better predictor of the disease 98 
outcomes. Consistent with the increased sensitivity and higher accuracy, we observe 99 
increased LR+/LR- ratios for both PFS (3.81 versus 4.88) and OS (2.43 versus 3.66) when 100 
both coding and non-coding mutations were considered together (Table S2A and S3A). In 101 
addition, the positive predictive value (PPV) which is a measure of the proportion of true 102 
positives out of all the outcomes predicted by the biomarker, is higher when non-coding 103 
mutation was included in the test than when coding-mutation alone was used as the test 104 
biomarker (98.3 versus 97.9% for PFS and 93.1 versus 91,5% for OS, Table S2B, S3B). 105 
In summary, our data confirm the prognostic importance of non-coding NOTCH1 mutations 106 
in patients requiring first-line treatment with chemotherapy as part of the UK CLL4 trial. 107 
Importantly, restricted analysis of exon 34 neglected to identify 19% of patients with 108 
pathogenic NOTCH1 mutations in its 3’ UTR region. In addition, we show that the 109 
discriminatory power of NOTCH1 mutation status to predict outcomes is improved with the 110 
inclusion of non-coding mutations. Taken together, our study supports the analysis of the 3’ 111 
UTR region of the NOTCH1 gene to identify additional patients with reduced survival. 112 
Several recent studies have provided conflicting data on the clinical significance of clonal 113 
and sub-clonal NOTCH1 mutations 8,14,15. Most recently, Nadeu and colleagues 114 
demonstrated that clonal mutations predicted for short OS while subclonal mutations 115 
predicted for short time to first treatment 9. It will be important to employ these same deep 116 
sequencing approaches to ascertain the clinical significance of sub-clonal NOTCH1 mutations 117 
in the clinical trials setting. The UK CLL4 trial benefits from long-term clinical follow-up and 118 
expansive associated clinico-biological data but only assessed the utility of traditional 119 
chemotherapy. Therefore, it will be necessary to establish the impact of non-coding 120 
NOTCH1 mutations in patients treated with chemo-immunotherapy, where they are likely to 121 
identify a significant number of additional patients destined to respond poorly to rituximab-122 
containing treatment regimens 6. Mutant NOTCH1 currently represents a therapeutic target 123 
in T-ALL, with several mechanistic approaches under clinical development, including γ-124 
secretase and metalloproteinases inhibitors, antibodies directed against the extracellular 125 
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domain of Notch1, and antagonists that act by directly targeting the Notch transactivation 126 
domain. Screening for non-coding NOTCH1 mutations identifies additional CLL patients with 127 
Notch1 activation, offering motivation for clinical trials development. Assuming these 128 
approaches are ultimately approved for the treatment of CLL, it will be critical to identify all 129 
patients that will benefit from these treatments, as there will be important clinical and cost 130 
implications. These studies will help establish a stratified and individualized approach to 131 
clinical management, including the more accurate selection of patients for targeted therapy.  132 
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Figure 1. The genomic and clinical characteristics of NOTCH1 non-coding and coding 
mutations in the LRF CLL4 trial. (A) The distribution of mutations in NOTCH1. The NOTCH1 
gene contains 34 exons and encodes a protein with a C-terminal TAD-PEST domain, which is 
a hotspot for mutation in CLL. Part of exon 34 and the 3’ UTR are magnified and the location 
of each mutation is shown; coding (white) and non-coding mutations (black) are indicated. 
Each dot represent a single mutation. (B) The mutual relationship between coding and non-
coding NOTCH1 mutations and other clinico-biological characteristics in CLL. Rows 
correspond to specific clinical and biological features and columns represent individual 
patients (only patients with a NOTCH1 mutation are shown). Boxes colored black and grey 
show the presence or absence of a parameter. A white box denotes that no data were 
available. (C) and (D) Kaplan-Meir plots showing progression-free survival and overall 
survival, respectively.  
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Table1. Univariate and multivariate Cox proportional hazard analysis of OS and PFS in CLL4 patients. 
Overall survival Progression-free survival 
Univariate Multivariate Univariate Multivariate 
Variable   Total Events Median 95% CI HR 95% CI P HR 95% CI P Total Events Median 95% CI HR 95% CI P HR 95% CI P 
NOTCH1 Wild-type 431 312 74.6 67.8-81.5               431 394 27.6 24.9-30.4              
Mutated 58 52 53.4 35.9-70.9 1.6 1.2-2.2 0.001 1.5 1.0-2.1 0.04 58 57 19.3 15.0-23.5 1.6 1.2-2.1 0.001 1.3 0.9-1.9 0.108 
SF3B1 Wild-type 364 250 79.1 71.8-86.3               364 326 26.5 23.1-29.9              
Mutated 73 66 54.3 47.3-61.4 1.7 1.3-2.2 <0.001 1.5 1.1-2.1 0.014 73 73 26.5 22.4-30.7 1.3 1.0-1.7 0.033 1.3 0.9-1.8 0.071 
Age           1.1 1.0-1.1 <0.001  1.1 1.0-1.1 <0.001          1 0.9-1.1 0.663  0.9 0.9-1.0 0.387 
Sex Male 366 281 70.1 61.4-78.9 366 341 25.0 21.9-28.0 
  Female 129 86 79.6 66.5-93.0 0.8 0.6-1.0 0.056  0.8 0.6-1.1 0.121  129 115 29.4 25.5-33.3 0.8 0.7-1.0 0.055  0.9 0.7-1.1 0.338 
Binet Satge A 112 76 80.6 63.4-97.7 112 104 27.2 23.8-30.7 
  B/C 383 291 71.5 64.6-78.3 1.3 1.0-1.7 0.049  1.5 1.1-2.1 0.013  383 352 26.1 23.0-29.1 0.9 0.8-1.3 0.995  1.2 0.9-1.5 0.433 
Del(11q) Undeleted 373 267 75 67.5-82.6 373 267 75 67.4-82.6 
  Deleted 92 79 57.7 42.4-73.0 1.6 1.3-2.1 <0.001  1.4 1.1-1.9 0.023  92 79 57.7 42.4-73.0 1.5 1.2-1.9 0.001  1.7 1.3-2.2 <0.001
IGHV status Mutated 155 91 104.2 93.3-115.1 155 91 104.2 93.3-115.1
  Unmutated 255 216 60.6 52-8-68.4 2.2 1.7-2.8 <0.001  1.9 1.4-2.5 <0.001  255 216 60.6 52.8-68.4 1.9 1.6-2.4 <0.001  1.8 1.4-2.4 <0.001
TP53 status Normal 431 313 75.9 69.3-82.1 431 313 75.9 69.7-82.1 
  Del/Mut 32 31 26.1 4.9-47.4 3.1 2.2-4.6 <0.001  2.5 1.5-4.1 <0.001  32 31 26.1 4.9-47.4 2.7 1.9-3.9 <0.001  2.2 1.3-3.5 0.002 
Treatment arm Chl 238 178 76.8 70.1-83.4 238 178 76.8 70.1-83.4 
  FDR/FC 257 189 68 57.9-78.1 1.1 0.9-1.3 0.426  0.9 0.8-1.3 0.854  257 189 68 57.9-78.1 0.6 0.5-0.7 <0.001  0.5 0.4-0.6 <0.001
 2
Footnote. Chl: chlorambucil, FDR: fludarabine, FC: fludarabine plus cyclophosphamide. OS multivariate: 342 cases with 252 events; 153 missing data. PFS multivariate: 342 cases with 315 events, 153 missing data 
